PLAT

Summary

Gene Symbol: PLAT
Description: plasminogen activator, tissue type
Alias: T-PA, TPA, tissue-type plasminogen activator, alteplase, plasminogen/activator kringle, reteplase, t-plasminogen activator
Species: human

Top Publications

  1. ncbi [Relation of an increase of von Willebrand factor in the blood, acute myocardial infarction, unstable angina and coronary thrombosis]
    J M Mossard
    Service de cardiologie, , CHU de Strasbourg
    Arch Mal Coeur Vaiss 82:1813-8. 1989
  2. pmc Developmental profile of tissue plasminogen activator in postnatal Long Evans rat visual cortex
    Sha Zheng
    Southwest Eye Hospital, Southwest Hospital, Third Military Medical University, Chongqing, China
    Mol Vis 14:975-82. 2008
  3. pmc Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
    Zaid Al-Hamodi
    Department of Molecular Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
    Cardiovasc Diabetol 10:23. 2011
  4. pmc Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor
    K Orth
    Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas 75235
    Proc Natl Acad Sci U S A 89:7422-6. 1992
  5. pmc Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1
    E L Madison
    Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas 75235
    Proc Natl Acad Sci U S A 87:3530-3. 1990
  6. pmc Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger an
    O F Wagner
    Department of Molecular Biology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam
    J Clin Invest 84:647-55. 1989
  7. doi Investigation of association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism frequency and plasma PAI-1 enzyme activity in patients with acute stroke
    Banu Kucukarabaci
    Department of Medical Biology, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey
    Genet Test 12:443-51. 2008
  8. ncbi Role of viral receptors TLR3, RIG-I and MDA5 in mesothelial tissue-type plasminogen activator and plasminogen activator inhibitor-1 synthesis
    Markus Wornle
    Medical Policlinic, Ludwig Maximillians University, Munich, Germany
    Thromb Haemost 101:1128-37. 2009
  9. doi Association of PAI-1 4G/5G and -844G/A gene polymorphisms and changes in PAI-1/tissue plasminogen activator levels in myocardial infarction: a case-control study
    Nesrine Abboud
    Research Unit of Hematological and Autoimmune Diseases, Faculty of Pharmacy, University of Monastir, Monastir, Tunisia
    Genet Test Mol Biomarkers 14:23-7. 2010
  10. doi Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes
    Jodi A Lee
    School of Biological Sciences, University of Wollongong, Northfields Avenue, Wollongong, New South Wales, Australia
    Thromb Haemost 104:1133-42. 2010

Research Grants

  1. Adjunctive Use of Apyrase to Fibrinolytic Therapy
    Ridong Chen; Fiscal Year: 2013
  2. MRI of Acute Vascular Injury and Hemorrhagic Transformation in Ischemic Stroke
    Robert A Knight; Fiscal Year: 2010
  3. Mini-plasmin: Pre-Clinical Evaluation of a Novel Thrombolytic Strategy for Stroke
    Irina Y Sazonova; Fiscal Year: 2012
  4. Daniel A Lawrence; Fiscal Year: 2016
  5. ERIK IAN TUCKER; Fiscal Year: 2016
  6. Keith B Neeves; Fiscal Year: 2014
  7. Phillip Zhe Sun; Fiscal Year: 2016
  8. Imaging Study of Combination Thrombolytic Therapy
    GEORGE JEROME SHAW; Fiscal Year: 2010
  9. Development of Stroke Point of Care Immunoassay for Cellular Fibronectin
    Albert K Man; Fiscal Year: 2010
  10. Thrombolysis in Pediatric Stroke Study (TIPS)
    Catherine M Amlie-Lefond; Fiscal Year: 2013

Patents

  1. Novel fibrinolytic enzymes
  2. Preparation of human tissue plasminogen activator (t-PA) by the microbiological way and conversion of the so obtained enzyme in its active form
  3. New tissue plasminogen activator

Detail Information

Publications557 found, 100 shown here

  1. ncbi [Relation of an increase of von Willebrand factor in the blood, acute myocardial infarction, unstable angina and coronary thrombosis]
    J M Mossard
    Service de cardiologie, , CHU de Strasbourg
    Arch Mal Coeur Vaiss 82:1813-8. 1989
    ..In conclusion, the VWF may be considered to be a marker for thrombus and/or endothelial activation but a larger study population would be required to identify more accurately the subgroups with thrombosis or risk of thrombosis...
  2. pmc Developmental profile of tissue plasminogen activator in postnatal Long Evans rat visual cortex
    Sha Zheng
    Southwest Eye Hospital, Southwest Hospital, Third Military Medical University, Chongqing, China
    Mol Vis 14:975-82. 2008
    To investigate the distribution, expression, and activity of tissue plasminogen activator (tPA) in the visual cortex of the Long Evans rat during postnatal development, and to explore the relationship between tPA levels and the critical ..
  3. pmc Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
    Zaid Al-Hamodi
    Department of Molecular Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
    Cardiovasc Diabetol 10:23. 2011
    Increased plasma plasminogen activator inhibitor-1 (PAI-1) activity and decreased tissue plasminogen activator (tPA) activity could be considered a true component of the metabolic syndrome (MetS) associated with an increased risk of ..
  4. pmc Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor
    K Orth
    Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas 75235
    Proc Natl Acad Sci U S A 89:7422-6. 1992
    ..We propose a role for LRP in the clearance of plasminogen activator-inhibitor complexes that is analogous to its function in the endocytosis of alpha 2-macroglobulin-protease complexes...
  5. pmc Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1
    E L Madison
    Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas 75235
    Proc Natl Acad Sci U S A 87:3530-3. 1990
    ....
  6. pmc Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger an
    O F Wagner
    Department of Molecular Biology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam
    J Clin Invest 84:647-55. 1989
    ..An implication of the proposed model is that t-PA/PAI-1 complexes and free t-PA compete for the same binding sites on fibrin...
  7. doi Investigation of association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism frequency and plasma PAI-1 enzyme activity in patients with acute stroke
    Banu Kucukarabaci
    Department of Medical Biology, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey
    Genet Test 12:443-51. 2008
    ..This study was carried out to determine if there is any association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism and plasma PAI-1 enzyme activity in acute stroke patients...
  8. ncbi Role of viral receptors TLR3, RIG-I and MDA5 in mesothelial tissue-type plasminogen activator and plasminogen activator inhibitor-1 synthesis
    Markus Wornle
    Medical Policlinic, Ludwig Maximillians University, Munich, Germany
    Thromb Haemost 101:1128-37. 2009
    ....
  9. doi Association of PAI-1 4G/5G and -844G/A gene polymorphisms and changes in PAI-1/tissue plasminogen activator levels in myocardial infarction: a case-control study
    Nesrine Abboud
    Research Unit of Hematological and Autoimmune Diseases, Faculty of Pharmacy, University of Monastir, Monastir, Tunisia
    Genet Test Mol Biomarkers 14:23-7. 2010
    ..Myocardial infarction (MI) is induced by acquired and inherited risk factors, including the plasminogen activator inhibitor-1 (PAI-1) -844G/A and -675G/A (4G/5G) gene variants...
  10. doi Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes
    Jodi A Lee
    School of Biological Sciences, University of Wollongong, Northfields Avenue, Wollongong, New South Wales, Australia
    Thromb Haemost 104:1133-42. 2010
    ....
  11. ncbi Thymosin beta 4 induces the synthesis of plasminogen activator inhibitor 1 in cultured endothelial cells and increases its extracellular expression
    Khalid N I Al-Nedawi
    Center for Medical Biology and Microbiology, Polish Academy of Sciences, Lodz, Poland
    Blood 103:1319-24. 2004
    ..Taken together, these data indicate that, in response to T beta 4 stimulation, AP-1 activity increases to enhance PAI-1 transcription through its unique AP-1-like element at -59 to -52 in the PAI-1 promoter...
  12. pmc 4G/5G polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome
    Muammer Karadeniz
    Endocrinology and Metabolism Disease, Ege University Hospital, 35100, Bornova, Izmir, Turkey
    J Assist Reprod Genet 24:412-8. 2007
    ..Polycystic ovary syndrome (PCOS) is one of the most encountered endocrine malfunctions. PCOS patients have enhanced activation of the blood coagulation system...
  13. doi Genetic architecture of tissue-type plasminogen activator and plasminogen activator inhibitor-1
    Folkert W Asselbergs
    Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Semin Thromb Hemost 34:562-8. 2008
    ....
  14. doi Galectin-1 is a novel functional receptor for tissue plasminogen activator in pancreatic cancer
    Oriol Roda
    Cancer Research Programme, Municipal Institute of Medical Research, Barcelona, Spain
    Gastroenterology 136:1379-90, e1-5. 2009
    Tissue plasminogen activator (tPA) exerts many different functions in addition to its role in fibrinolysis...
  15. pmc Epistatic interactions in genetic regulation of t-PA and PAI-1 levels in a Ghanaian population
    Nadia M Penrod
    Department of Genetics, Dartmouth Medical School, Lebanon, New Hampshire, United States of America
    PLoS ONE 6:e16639. 2011
    ..006) and the REN T9435C and the TPA I/D polymorphisms (p = 0.005) in males...
  16. ncbi The relationship between plasma t-PA and PAI-1 levels is dependent on epistatic effects of the ACE I/D and PAI-1 4G/5G polymorphisms
    J H Moore
    Program in Human Genetics, Department of Molecular Physiology and Biophysics, 519 Light Hall, Vanderbilt University Medical School, Nashville, TN 37232 0700, USA
    Clin Genet 62:53-9. 2002
    ..This study supports the idea that interactions between the fibrinolytic and renin-angiotensin systems play an important role in the genetic architecture of plasma t-PA and PAI-1...
  17. ncbi Glycation does not alter LDL-induced secretion of tissue plasminogen activator and plasminogen activator inhibitor-1 from human aortic endothelial cells
    Richard L Klein
    Division of Endocrinology Diabetes Medical Genetics, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Ann N Y Acad Sci 1043:379-89. 2005
    ..Effects of LDL glycation on endothelial cell secretion of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) have not been fully elucidated...
  18. ncbi The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1
    C Thelwell
    National Institute for Biological Standards and Control, South Mimms, Herts, UK
    J Thromb Haemost 5:804-11. 2007
    Tissue plasminogen activator (tPA) is unusual in the coagulation and fibrinolysis cascades in that it is produced as an active single-chain enzyme (sctPA) rather than a zymogen...
  19. ncbi Mcp-1, eNOS, tPA and PAI-1 gene polymorphism and correlation of genotypes and phenotypes in hepatopulmonary syndrome
    Gokhan Tumgor
    Department of Pediatric Gastroenterology, Hepatology and Nutrition and Organ Transplantation and Research Center, Ege University School of Medicine, Izmir, Turkey
    Dig Dis Sci 53:1345-51. 2008
    The aim of this case-control study was to investigate both the distribution of MCP-1, eNOS, tPA and PAI-1 gene polymorphism and correlation of genotypes and phenotypes.
  20. pmc Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling
    Kebin Hu
    Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA
    J Clin Invest 117:3821-32. 2007
    ..Here we describe a signaling pathway that leads to this activation. Tissue-type plasminogen activator (tPA) promoted TGF-beta1-mediated alpha-SMA and type I collagen expression in rat kidney interstitial fibroblasts...
  21. doi Human plasminogen kringle 1-5 reduces atherosclerosis and neointima formation in mice by suppressing the inflammatory signaling pathway
    P C Chang
    Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
    J Thromb Haemost 8:194-201. 2010
    ..Kringle 1-5 (K(1-5)) is a variant of angiostatin that contains the first five kringle domains of plasminogen...
  22. ncbi Tissue-type plasminogen activator -7,351C/T enhancer polymorphism is associated with a first myocardial infarction
    Per Ladenvall
    Cardiovascular Institute, Clinical Experimental Research Laboratory, Sahlgrenska University Hospital Ostra, Goteborg University, Sweden
    Thromb Haemost 87:105-9. 2002
    We recently identified a polymorphic Sp1 binding site in an enhancer at the tissue-type plasminogen activator (tPA) locus (tPA -7,351C/T), which was associated with vascular tPA release...
  23. ncbi Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II
    Chia Jen Siao
    Department of Pharmacological Sciences and Program in Molecular and Cellular Pharmacology, University Medical Center at Stony Brook, Stony Brook, New York 11794 8651, USA
    J Neurosci 22:3352-8. 2002
    ..One molecule whose expression is upregulated after excitotoxic injury is tissue plasminogen activator (tPA), a serine protease with dual roles in the CNS...
  24. ncbi Tissue plasminogen activator -7351C/T enhancer polymorphism is a risk factor for lacunar stroke
    Jim Jannes
    Department of Medicine, University of Adelaide, The Queen Elizabeth Hospital, Woodville South, South Australia
    Stroke 35:1090-4. 2004
    ..Endogenous tissue plasminogen activator (TPA) is the primary mediator of intravascular fibrinolysis and is predominantly expressed by the endothelium of small ..
  25. ncbi Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system
    Tambet Teesalu
    Haartman Institute, University of Helsinki and HUCH Laboratory Diagnostics, Finland
    Thromb Haemost 92:358-68. 2004
    Tissue plasminogen activator (tPA) is increasingly recognized to play important roles in various physiological and pathological processes in the central nervous system (CNS)...
  26. ncbi The t-PA -7351C>T enhancer polymorphism decreases Sp1 and Sp3 protein binding affinity and transcriptional responsiveness to retinoic acid
    Anna Tjärnlund Wolf
    Institute of Clinical Neuroscience, Sahlgrenska University Hospital Sahlgrenska, Goteborg University, S 413 45 Goteborg, Sweden
    Blood 105:1060-7. 2005
    ..The reduced binding affinity of Sp1/Sp3 to the T allele could explain our earlier observations of a reduced t-PA release and an increased risk of myocardial infarction in individuals carrying this allele...
  27. pmc Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation
    Manel G Medina
    Unitat de Biologia Cel lular i Molecular, IMIM, Barcelona, Spain
    EMBO J 24:1706-16. 2005
    Tissue plasminogen activator (tPA) is the main activator of plasminogen into plasmin in the brain where it may have beneficial roles but also neurotoxic effects that could be plasmin dependent or not...
  28. pmc Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels
    Folkert W Asselbergs
    Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands
    Genomics 89:362-9. 2007
    ..These results support the idea that the interplay between the renin-angiotensin, bradykinin, and fibrinolytic systems might play an important role in t-PA and PAI-1 biology...
  29. ncbi PAI and TPA gene polymorphisms in multiple sclerosis
    Luca Lovrecic
    Division of Medical Genetics, UMC, Ljubljana, Slovenia
    Mult Scler 14:243-7. 2008
    ..Alu insertion/deletion (I/D) genetic polymorphism in TPA gene in MS patients has not been analysed previously...
  30. pmc Male-female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population
    J A Schoenhard
    Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical School, Nashville, TN, USA
    Hum Genet 124:479-88. 2008
    ..significant relationship was found between the PAI-1 4G/5G (rs1799768) polymorphism on PAI-1 levels in females, the TPA I/D (rs4646972) polymorphism on t-PA and PAI-1 in males, the renin (rs3730103) polymorphism on t-PA and PAI-1 in ..
  31. doi Impact of COX-2 rs5275 and rs20417 and GPIIIa rs5918 polymorphisms on 90-day ischemic stroke functional outcome: a novel finding
    Jane Maguire
    School of Medicine and Public Health, Faculty of Health, University of Newcastle, Callaghan, New South Wales, Australia
    J Stroke Cerebrovasc Dis 20:134-44. 2011
    ..glycoprotein Ibα (GPIbα) rs224309 and rs6065, glycoprotein IIIa (GPIIIa) rs5918, tissue plasminogen activator (tPA) rs63020761, plasminogen activating inhibitor (PAI-1) rs72578597, and cyclooxygenase-2 (COX-2) rs5275 and rs20417...
  32. doi Surface-retained tPA is essential for effective fibrinolysis on vascular endothelial cells
    Yuko Suzuki
    Department of Physiology, Hamamatsu University School of Medicine, Hamamatsu, Japan
    Blood 118:3182-5. 2011
    In a previous study, we demonstrated unique secretory dynamics of tissue plasminogen activator (tPA) in which tPA was retained on the cell surface in a heavy chain-dependent manner after exocytosis from secretory granules in vascular ..
  33. pmc A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue-type plasminogen activator
    Paul Y Kim
    Departments of Medicine and Biochemistry and Biomedical Sciences, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario L8L 2X2, Canada
    J Biol Chem 287:4652-61. 2012
    Fibrin (Fn) enhances plasminogen (Pg) activation by tissue-type plasminogen activator (tPA) by serving as a template onto which Pg and tPA assemble...
  34. doi Association of genetic variants of fibrinolytic system with stroke and stroke subtypes
    M Sai Babu
    Institute of Genetics and Hospital for Genetic Diseases, Osmania University, Begumpet, Hyderabad 500016, India
    Gene 495:76-80. 2012
    Genetic variants of tPA (PLAT) and PAI-1 genes have been suggested to be the risk factors for stroke...
  35. ncbi The PAI-1 4G/5G gene polymorphism and ischemic stroke: an association study and meta-analysis
    John Attia
    Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, Newcastle NSW Australia
    J Stroke Cerebrovasc Dis 16:173-9. 2007
    ..The results also sound a cautionary note that varying LD structure across populations may obscure the relationship with a causative locus, and that future meta-analyses need to look beyond a simple pooled estimate...
  36. doi Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells
    Yuko Suzuki
    Department of Physiology, Hamamatsu University School of Medicine, Hamamatsu, Japan
    Blood 113:470-8. 2009
    We analyzed the secretory dynamics of tissue plasminogen activator (tPA) in EA.hy926 cells, an established vascular endothelial cell (VEC) line producing GFP-tagged tPA, using total internal reflection-fluorescence (TIR-F) microscopy...
  37. doi Tissue plasminogen activator (tPA) activity is a novel and early marker of asymptomatic LEAD in type 2 diabetes
    David Sahli
    Department of Medicine, Umea University Hospital, Umea, Sweden
    Thromb Res 123:701-6. 2009
    ..Lower extremity arterial disease (LEAD) is often one of the first signs of a generalized atherosclerotic disease in type 1 and type 2 diabetic subjects...
  38. doi Role of tissue plasminogen activator and plasminogen activator inhibitor polymorphism in myocardial infarction
    Waqas Ahmed
    Department of Biosciences, COMSATS Institute of Information Technology, Park Road, Islamabad, 45600, Pakistan
    Mol Biol Rep 38:2541-8. 2011
    ..72, OR=3.7 (95% CI=1.71-8.18)) and lower HDL levels (P<0.05) were found to be significantly associated with the disease. In conclusion the PAI-1 gene polymorphism was found to have a gender specific role in the female MI patients...
  39. ncbi Fibrinolytic gene polymorphism and ischemic stroke
    Katarina Jood
    Institute of Clinical Neuroscience, The Sahlgrenska Academy, Goteborg University, Goteborg, Sweden
    Stroke 36:2077-81. 2005
    The tissue-type plasminogen activator (tPA) -7351C>T and the plasminogen activator inhibitor type 1 (PAI-1) -675 4G>5G polymorphisms influence transcriptional activity...
  40. ncbi Tissue plasminogen activator and plasminogen activator inhibitor-1 gene polymorphisms in patients with chronic periodontitis
    Ali Gürkan
    Department of Periodontology, School of Dentistry, Ege University, Izmir, Turkey
    J Periodontol 78:1256-63. 2007
    ..This study was designed to investigate the association of t-PA and PAI-1 gene polymorphisms with chronic periodontitis (CP)...
  41. ncbi IL-8 induces imbalances between nitric oxide and endothelin-1, and also between plasminogen activator inhibitor-1 and tissue-type plasminogen activator in cultured endothelial cells
    Min Cheng
    Laboratory of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China
    Cytokine 41:9-15. 2008
    ..Furthermore, IL-8 also leads to an imbalance between PAI-1 and t-PA, which causes the ECs to become procoagulative and hypofibrinolytic...
  42. ncbi Design of novel thrombolytic agents via domain modifications
    L A Erickson
    Cardiovascular Diseases and Molecular Biology Research, Upjohn Laboratories Kalamazoo, Michigan 49001
    Toxicol Pathol 18:597-602. 1990
    ..The available data suggest that tissue-type PA (tPA) mutants possessing resistance to endogenous inhibitors, altered fibrin affinity, and/or slower rates of clearance ..
  43. ncbi Lewis phenotypes and the insulin resistance syndrome in young healthy white men and women
    J O Clausen
    Medical Department C, Glostrup Hospital, Copenhagen, Denmark
    Am J Hypertens 8:1060-6. 1995
    ..In young women no signs of the insulin resistance syndrome were found in subjects with the Le(a-b-) phenotype...
  44. ncbi Impaired fibrinolysis and insulin resistance in patients with hypertension
    J R Jeng
    Division of Cardiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Republic of China, Taiwan
    Am J Hypertens 9:484-90. 1996
    Plasma plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator (tPA) antigens and activities were measured in 28 patients with hypertension and 12 normal controls...
  45. ncbi Plasminogen activator inhibitor-1 and angiotensin I converting enzyme gene polymorphism in patients with hypertension
    J R Jeng
    Division of Cardiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
    Am J Hypertens 11:235-9. 1998
    ..The ACE genotypes may not have a role in influencing the fibrinolysis in hypertension...
  46. ncbi Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension
    Y Erdem
    Department of Nephrology, Hacettepe University School of Medicine, Ankara, Turkey
    Am J Hypertens 12:1071-6. 1999
    ..The beneficial effect of ACE inhibitors on fibrinolysis seems to be related to the blockade of Ang-II, and increased kinin activity does not appear to play a major role...
  47. ncbi Kinetic analysis of covalent hybrid plasminogen activators: effect of CNBr-degraded fibrinogen on kinetic parameters of Glu1-plasminogen activation
    P P Lee
    Department of Medicine, University of Chicago Medical Center/Michael Reese Hospital and Medical Center, Pritzker School of Medicine, University of Chicago, Illinois 60616
    Biochemistry 27:7506-13. 1988
    ..CNBr-Fg enhanced significantly the activities of only two activators, t-PA and PlnA-t-PAB...
  48. ncbi A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction
    S C Kalish
    Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
    J Gen Intern Med 10:321-30. 1995
    ..costs and clinical and quality of life outcomes with the use of streptokinase (SK) vs tissue plasminogen activator (tPA) for acute myocardial infarction (MI). DESIGN: A decision analysis model...
  49. ncbi Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin
    J M Herbert
    Haemobiology Research Department, Sanofi Recherche, Toulouse, France
    Circ Res 79:590-600. 1996
    ..In the rabbit, intravenous injection of SANORG 32701 enhanced tissue plasminogen activator (TPA)-induced thrombolysis, suggesting that concomitant use of SANORG 32701 during TPA therapy may be helpful in ..
  50. ncbi Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria
    S Gasic
    Department of Internal Medicine III, University Hospital of Vienna, Wien, Austria
    Am J Hypertens 12:217-22. 1999
    ..effects of ACE-I on plasma levels of plasminogen activator inhibitor (PAI-1) and of tissue plasminogen activator (TPA) were studied...
  51. ncbi Alterations in the fibrinolytic system components during acute myocardial infarction
    E Ioannidou Papayannaki
    Haematology Laboratory of 2nd Dept of Internal Medicine, Aristotelian University of Thessaloniki, Hippokration Hospital, Greece
    Acta Cardiol 55:247-53. 2000
    ....
  52. ncbi [Tissue plasminogen activator (alteplase) in acute massive pulmonary embolism. A pilot study]
    M Lang
    Clinique cardiologique, CHU Trousseau, Tours
    Arch Mal Coeur Vaiss 82:1803-11. 1989
    ..by bilateral pulmonary angiography with a Miller index greater than 15 were given tissue plasminogen activator (Alteplase) (rt-PA) intravenously (n = 20) or directly into the pulmonary artery (n = 6)...
  53. ncbi A comparison of irrigation solutions for microanastomoses
    C A Reichel
    Division of Plastic and Reconstructive Surgery, University of Missouri Health Sciences Center, Columbia 65212
    J Hand Surg Am 13:33-6. 1988
    ..was compared with solutions of heparin (35%) urokinase (50%), phentolamine (35%) tissue plasminogen activator (tPA) (15%), a combination of urokinase, heparin, and phentolamine (55%), and a combination of tPA, heparin, and ..
  54. ncbi Community hospital experience with recombinant tissue plasminogen activator in acute myocardial infarction
    S M Austin
    Department of Internal Medicine, St. Elizabeth Hospital Medical Center, Youngstown, OH 44501-1790
    J Gen Intern Med 7:187-90. 1992
    ..who had had acute myocardial infarction (MI) and who had received intravenous tissue plasminogen activator (TPA) at a community teaching hospital were reviewed retrospectively...
  55. ncbi VEGF and tPA co-expressed in malignant glioma
    M Lindgren
    Department of Oncology, , Sweden
    Acta Oncol 36:615-8. 1997
    ..Vascular endothelial growth factor (VEGF) and tissue plasminogen activator (tPA) seem to be of importance in the process of malignancy...
  56. ncbi Decreased fibrinolytic activity and increased platelet function in hypertension. Possible influence of calcium antagonism
    G Gleerup
    Medical Department B, Frederiksberg Hospital, Copenhagen
    Am J Hypertens 4:168S-171S. 1991
    ..Besides the blood pressure-lowering effect, isradipine may protect against thromboembolic diseases by modifying platelet function and fibrinolytic activity...
  57. ncbi DRL performance in mice with deletion of tPA, uPA or PAI-1 genes
    J M Horwood
    Laboratory of Experimental Psychology, University of Sussex, Falmer, Brighton, BN1 9QG, UK
    Behav Pharmacol 12:487-96. 2001
    ..into two distinct subtypes, tissue plasminogen activating factor and urokinase plasminogen activating factor (tPA and uPA, respectively), which are both expressed in brain areas thought to be important in learning and memory...
  58. pmc Mechanism of angiogenic effects of saponin from ginseng Radix rubra in human umbilical vein endothelial cells
    N Morisaki
    Second Department of Internal Medicine, School of Medicine, Chiba University, Japan
    Br J Pharmacol 115:1188-93. 1995
    ..The activity and immunoreactivity of tissue-type plasminogen activator (tPA) as a protease for angiogenesis and the immunoreactivity of its inhibitor, plasminogen activator inhibitor-1 (PAI-1)..
  59. ncbi Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin
    S T Olson
    Center for Molecular Biology of Oral Diseases, University of Illinois at Chicago, Chicago, Illinois 60612, USA
    Biochemistry 40:11742-56. 2001
    ..in the reactions of the serpin, plasminogen activator inhibitor-1 (PAI-1), with tissue plasminogen activator (tPA) and trypsin by comparing the reactions of active and Ser 195-inactivated enzymes with site-specific fluorescent-..
  60. ncbi The search for the ideal thrombolytic agent: maximize the benefit and minimize the risk
    S J Gardell
    Department of Biological Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486
    Toxicol Pathol 21:190-8. 1993
    Streptokinase, acylated plasminogen streptokinase complex, and tissue-type plasminogen activator (tPA) are widely used for the treatment of acute myocardial infarction...
  61. ncbi Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke
    L Johansson
    Department of Medicine, Skellefteå County Hospital, Umea, Sweden
    Stroke 31:26-32. 2000
    ..This study was designed to test whether plasma levels of tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), and tPA/PAI-1 complex could predict a first-ever stroke.
  62. doi Biphasic regulation of tissue plasminogen activator activity in ischemic rat brain and in cultured neural cells: essential role of astrocyte-derived plasminogen activator inhibitor-1
    Ji Woon Kim
    Department of Pharmacology, Research Institute of Medical Sciences and Institute of Functional Genomics, Konkuk University, Seoul, Republic of Korea
    Neurochem Int 58:423-33. 2011
    In brain, the serine protease tissue plasminogen activator (tPA) and its endogenous inhibitor plasminogen activator inhibitor-1 (PAI-1) have been implicated in the regulation of various neurophysiological and pathological responses...
  63. ncbi Fibrinolysis therapy achieved with tissue plasminogen activator and aspiration of the liquefied clot after experimental intracerebral hemorrhage: rapid reduction in hematoma volume but intensification of delayed edema formation
    Veit Rohde
    Department of Neurosurgery, Aachen University, Germany
    J Neurosurg 97:954-62. 2002
    Fibrinolysis therapy accomplished using tissue plasminogen activator (tPA) and aspiration is considered to be a viable alternative to microsurgery and medical therapy for the treatment of deep-seated spontaneous intracerebral hematomas (..
  64. ncbi Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study
    B Wiman
    Department of Clinical Chemistry, Karolinska Hospital, Stockholm, Sweden
    Arterioscler Thromb Vasc Biol 20:2019-23. 2000
    ..due to elevated plasma levels of plasminogen activator inhibitor (PAI)-1 activity or tissue plasminogen activator (tPA) antigen is correlated with the development of myocardial infarction (MI) in patients with manifest coronary heart ..
  65. doi Exacerbation of perihematomal edema and sterile meningitis with intraventricular administration of tissue plasminogen activator in patients with intracerebral hemorrhage
    Andrew F Ducruet
    Department of Neurological Surgery, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    Neurosurgery 66:648-55. 2010
    ..External ventricular drainage together with clot lysis through intrathecal tissue plasminogen activator (IT-tPA) has been proposed as a promising therapy...
  66. ncbi The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study
    Thomas Kwiatkowski
    Department of Emergency Medicine, Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA
    Ann Emerg Med 45:377-84. 2005
    ..Study demonstrated a clinically meaningful and statistically significant benefit of tissue plasminogen activator (tPA). Adjusting for the baseline National Institutes of Health (NIH) Stroke Scale, the benefit of tPA remained...
  67. ncbi Measurement of different forms of tissue plasminogen activator in plasma
    W L Chandler
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA
    Clin Chem 46:38-46. 2000
    We evaluated assays to measure both total tissue plasminogen activator (tPA) and the three principle forms of tPA in plasma: active tPA, tPA complexed with plasminogen activator inhibitor type 1 (PAI-1), and tPA complexed with C1-..
  68. ncbi Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels
    W L Chandler
    Department of Laboratory Medicine, University of Washington, Seattle 98195 7110, USA
    Circulation 96:761-8. 1997
    ..of plasminogen activator inhibitor type 1 (PAI-1) levels on the clearance of total tissue plasminogen activator (TPA) antigen, we studied the clearance of active TPA and TPA/PAI-1 complex in subjects with low (181+/-109 pmol/L; n=7) ..
  69. ncbi Hypertriglyceridemic VLDL downregulates tissue plasminogen activator gene transcription through cis-repressive region(s) in the tissue plasminogen activator promoter in cultured human endothelial cells
    E M Tabengwa
    Division of Cardiovascular Disease, University of Alabama at Birmingham, USA uab edu
    Arterioscler Thromb Vasc Biol 20:1675-81. 2000
    The relationship between tissue plasminogen activator (tPA) levels and the potential regulation by hypertriglyceridemic very low density lipoprotein (HTG-VLDL) was examined in a human umbilical vein endothelial cell (HUVEC) culture model ..
  70. ncbi [Intravenous administration of a tissue plasminogen activator beyond 3 hours of the onset of acute ischemic stroke--MRI-based decision making]
    Wataru Kakuda
    Department of Rehabilitation Medicine, Jikei University School of Medicine, 3 19 18 Nishi shinbashi, Minato ku, Tokyo 105 8471, Japan
    Brain Nerve 60:1173-80. 2008
    ..stroke patients who showed PWI/DWI mismatch after 3 to 6 hours of the onset were assigned to receive either alteplase or placebo administration: lesion growth was lesser in patients with alteplase than in those who received ..
  71. ncbi Thrombolysis for acute ischemic stroke in Taiwan
    A Ching Chao
    Acta Neurol Taiwan 19:225-7. 2010
  72. doi Differential regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by the cyclic-AMP system in lipopolysaccharide-stimulated rat primary astrocytes
    Soon Young Lee
    Department of Pharmacology, School of Medicine and Center for Geriatric Neuroscience Research, Institute of Biomedical Science and Technology, Konkuk University, 1 Hwayang dong, Gwangjin gu, Seoul, 143 701, South Korea
    Neurochem Res 33:2324-34. 2008
    ..LPS)-induced changes in the activity of matrix metalloproteinases (MMPs) and tissue plasminogen activator (tPA) in rat primary astrocytes. LPS stimulation increased MMP-9 and decreased tPA activity in rat primary astrocytes...
  73. ncbi Clinical and vascular outcome in internal carotid artery versus middle cerebral artery occlusions after intravenous tissue plasminogen activator
    Italo Linfante
    Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Mass 02115, USA
    Stroke 33:2066-71. 2002
    ..cerebral artery (MCA) occlusions have a better clinical outcome and proportion of recanalization compared with internal carotid artery (ICA) occlusion after standard treatment with intravenous (IV) tissue plasminogen activator (tPA).
  74. ncbi The expression of endothelial tissue plasminogen activator in vivo: a function defined by vessel size and anatomic location
    E G Levin
    Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA 92037, USA
    J Cell Sci 110:139-48. 1997
    Plasma tissue plasminogen activator (tPA) has long been considered to be the product of the endothelial cells that line the various parts of the vascular system regardless of vessel size or location...
  75. ncbi Increased retinal toxicity of intravitreal tissue plasminogen activator in a central retinal vein occlusion model
    Takuhiro Yamamoto
    Department of Ophthalmology, E7, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita 565 0871, Japan
    Graefes Arch Clin Exp Ophthalmol 246:509-14. 2008
    Intravitreal injection of tissue plasminogen activator (tPA) is used to treat several ocular conditions, although excessive doses of intravitreal tPA cause retinal toxicity...
  76. ncbi Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire
    Michael I Weintraub
    Department of Neurology and Internal Medicine, New York Medical College, Valhalla, NY, USA
    Stroke 37:1917-22. 2006
    ..Institutes of Neurological Disorders and Stroke (NINDS) study using IV recombinant tissue plasminogen activator (tPA) within 3 hours in acute stroke and its subsequent FDA approval, there has been a reluctance to use tPA because of ..
  77. ncbi Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke
    P A Lapchak
    Department of Neuroscience, University of California at San Diego, La Jolla 92093 0624, USA
    Stroke 31:3034-40. 2000
    A potentially dangerous side effect associated with tissue plasminogen activator (tPA) use is cerebral hemorrhage. We have focused on developing drugs that could be administered with tPA to reduce the rate of hemorrhage...
  78. ncbi Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6, 6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator
    P A Lapchak
    Department of Neuroscience, University of California at San Diego, La Jolla, CA 92093 0624, USA
    Stroke 32:147-53. 2001
    ..pharmacological agent for the treatment of stroke, the thrombolytic tissue plasminogen activator (tPA). Thus, we determined the effects of PBN when administered before tPA on hemorrhage and infarct rate and volume...
  79. pmc Aggressive blood pressure-lowering treatment before intravenous tissue plasminogen activator therapy in acute ischemic stroke
    Sheryl Martin-Schild
    Vascular Neurology Program, Department of Neurology, University of Texas Health Science Center at Houston, 6431 Fannin St, Medical School Bldg Room 7 128, Houston, TX 77030, USA
    Arch Neurol 65:1174-8. 2008
    ..Guidelines have recommended against treatment with intravenous tissue plasminogen activator (tPA) when aggressive measures such as continuous infusion with nicardipine hydrochloride are required to maintain BP ..
  80. doi Knowledge of tissue plasminogen activator for acute stroke among Michigan adults
    Beth E Anderson
    Michigan Department of Community Health, Chronic Disease Epidemiology Section, Lansing, MI 48909, USA
    Stroke 40:2564-7. 2009
    Although tissue plasminogen activator (tPA) is an effective therapy for acute ischemic stroke, treatment rates remain low...
  81. ncbi Thrombosed hemodialysis grafts: lyse and wait with tissue plasminogen activator or urokinase compared to mechanical thrombolysis with the Arrow-Trerotola Percutaneous Thrombolytic Device
    P M Vogel
    Sutter Medical Center, Sacramento, California, USA
    J Vasc Interv Radiol 12:1157-65. 2001
    To determine if the lyse and wait (L&W) technique with a 4-mg dose of alteplase (tissue plasminogen activator; tPA) is a safe and effective method of declotting dialysis grafts as compared to use of the Arrow-Trerotola Percutaneous ..
  82. pmc Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells
    Mariano Hurtado
    Unitat de Recerca Biomedica, Institut de Recerca, Hospital Vall d Hebron, Pg Vall d Hebron 119 129, Barcelona 08035, Spain
    Gut 56:1266-74. 2007
    Tissue plasminogen activator (tPA) is the major activator of plasminogen in plasma. This serine protease is overexpressed by exocrine pancreas tumour cells, where it promotes tumour cell proliferation, growth, and invasion...
  83. ncbi Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia
    Kiyoshi Tsuji
    Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA
    Stroke 36:1954-9. 2005
    Thrombolytic therapy with tissue plasminogen activator (tPA) in ischemic stroke is limited by increased risks of cerebral hemorrhage and brain injury...
  84. ncbi Peroxynitrite inactivates tissue plasminogen activator
    Vance G Nielsen
    Department of Anesthesiology, The Center for Free Radical Biology, The University of Alabama at Birmingham, Birmingham, Alabama 35249 6810, USA
    Anesth Analg 98:1312-7, table of contents. 2004
    Tissue plasminogen activator (tPA) has a prominent role in physiological fibrinolysis in vivo. Thrombosis has been associated with clinical scenarios (e.g...
  85. ncbi The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke
    Paul A Lapchak
    Department of Neuroscience, University of California at San Diego, La Jolla 92093 0624, USA
    Stroke 33:147-52. 2002
    ..leading to the "no-reflow" phenomenon after administration of the thrombolytic tissue plasminogen activator (tPA)...
  86. ncbi Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator
    Paul A Lapchak
    Department of Neuroscience, University of California at San Diego, La Jolla 92093 0624, USA
    Stroke 33:1665-70. 2002
    ..pharmacological agent for the treatment of stroke, the thrombolytic tissue plasminogen activator (tPA)...
  87. ncbi Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator
    Paul A Lapchak
    University of California San Diego, Department of Neuroscience, MTF 316, 9500 Gilman Dr, La Jolla, Calif 92093 0624, USA
    Stroke 34:2013-8. 2003
    ..Therefore, we determined the effects of ebselen when administered alone or with the thrombolytic tissue plasminogen activator (tPA), the only Food and Drug Administration-approved pharmacological agent for the treatment of stroke.
  88. doi Endovascular thrombectomy for acute ischemic stroke in failed intravenous tissue plasminogen activator versus non-intravenous tissue plasminogen activator patients: revascularization and outcomes stratified by the site of arterial occlusions
    Zhong Song Shi
    Division of Interventional Neuroradiology, David Geffen School of Medicine at UCLA, 757 Westwood Plaza, Los Angeles, CA 90095 7437, USA
    Stroke 41:1185-92. 2010
    ..is a therapeutic option for acute ischemic stroke patients failing intravenous tissue plasminogen activator (IV tPA)...
  89. ncbi An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase
    David M Kent
    Division of Clinical Care Research, Department of Medicine, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Am J Med 113:104-11. 2002
    In the Global Utilization of Streptokinase and tPA for Occluded coronary arteries (GUSTO) trial, patients with myocardial infarction who were treated with tissue plasminogen activator (tPA) had a 6...
  90. ncbi Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients
    Jose Alvarez-Sabin
    Cerebrovascular Unit, Department of Neurology, Hospital Vall d Hebron, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    Stroke 34:1235-41. 2003
    We sought to investigate the impact of hyperglycemia before reperfusion on long-term outcome in patients treated with intravenous tissue plasminogen activator (tPA).
  91. doi Reduction of early vein graft thrombosis by tissue plasminogen activator gene transfer
    Anita C Thomas
    Bristol Heart Institute, University of Bristol, Bristol, United Kingdom
    Thromb Haemost 102:145-52. 2009
    ..Saphenous vein lumen was exposed to adenovirus ex vivo, to over-express human tissue plasminogen activator (h-tPA), with beta-galactosidase adenovirus as a control...
  92. ncbi Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke
    A I Qureshi
    Department of Neurosurgery, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, USA
    Neurosurgery 49:41-8; discussion 48-50. 2001
    We prospectively evaluated the safety and recanalization efficacy of intra-arterially administered reteplase, a third-generation recombinant tissue plasminogen activator, for treating ischemic stroke in patients considered poor ..
  93. ncbi Distribution of sympathetic tissue plasminogen activator (tPA) to a distant microvasculature
    James O'Rourke
    University of Connecticut Health Center, Farmington, CT 06030 3105, USA
    J Neurosci Res 79:727-33. 2005
    Tissue plasminogen activator (tPA) is the predominant plasminogen activator present in the vascular and nervous systems. Prior studies of the two have emphasized different tPA sources; respectively, endothelium and neurons...
  94. ncbi Interaction and regulation of plasminogen activators and their inhibitor in rat follicles during periovulatory periods
    Y X Liu
    Department of Endocrinology, Institute of Zoology, Academia Sinica, Beijing
    Sci Sin B 31:47-57. 1988
    Ovarian follicles produce two types of plasminogen activator (tPA and uPA), and their inhibitor (PAI)...
  95. ncbi Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator
    Carlos A Molina
    Department of Neurology, Universitat Autonoma de Barcelona, Hospital Vall d Hebron, Barcelona, Spain
    Stroke 37:425-9. 2006
    ....
  96. ncbi Targeting of tissue plasminogen activator into the regulated secretory pathway of neuroendocrine cells
    L Santell
    Roon Research Center for Arteriosclerosis and Thrombosis, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA
    Brain Res 816:258-65. 1999
    Plasma levels of tissue plasminogen activator (tPA) increase rapidly in response to specific vasoactive agents, trauma, and neural stimulation...
  97. ncbi A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study
    I K Jang
    Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    J Am Coll Cardiol 33:1879-85. 1999
    This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).
  98. ncbi Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators
    C M Gibson
    Department of Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA
    Am J Cardiol 84:976-80. 1999
    ..We hypothesized that higher doses of TNK-tissue plasminogen activator (tPA) per unit body weight would be related to improved flow at 90 minutes after thrombolytic administration...
  99. ncbi Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older : the tPA stroke survey experience
    D Tanne
    Departments of Neurology, Henry Ford Health Science Center, Detroit, MI, USA
    Stroke 31:370-5. 2000
    Intravenous tissue plasminogen activator (tPA) administered within 3 hours of symptom onset is the first available effective therapy for acute ischemic stroke (AIS). Few data exist, however, on its use in very elderly patients...
  100. ncbi Determination of a weight-adjusted dose of TNK-tissue plasminogen activator
    F Wang-Clow
    Genentech, Inc, South San Francisco, USA
    Am Heart J 141:33-40. 2001
    TNK-tissue plasminogen activator (TNK-tPA) is a potent new thrombolytic agent for treatment of acute myocardial infarction...
  101. ncbi Tissue plasminogen activator protects hippocampal neurons from oxygen-glucose deprivation injury
    M P Flavin
    Department of Pediatrics, Queen s University, Kingston, Ontario, Canada
    J Neurosci Res 63:388-94. 2001
    We have previously shown that tissue plasminogen activator (tPA) participates in the neurotoxicity of microglial conditioned medium (MgCM)...

Research Grants67

  1. Adjunctive Use of Apyrase to Fibrinolytic Therapy
    Ridong Chen; Fiscal Year: 2013
    ..With the Phase I award, we demonstrated that in the r-tPA induced fibrinolysis model in dogs, treatment of APT102 completely prevented re-occlusion, maintained normal blood ..
  2. MRI of Acute Vascular Injury and Hemorrhagic Transformation in Ischemic Stroke
    Robert A Knight; Fiscal Year: 2010
    ..Thrombolytic therapy with tissue plasminogen activator (tPA) acts to increase blood flow to the ischemic tissue and is the only approved treatment for acute ischemic stroke...
  3. Mini-plasmin: Pre-Clinical Evaluation of a Novel Thrombolytic Strategy for Stroke
    Irina Y Sazonova; Fiscal Year: 2012
    ..the testing of over 70 agents in clinical trials, only one drug, the recombinant tissue plasminogen activator (TPA), has been approved by the FDA for the treatment of ischemic stroke...
  4. Daniel A Lawrence; Fiscal Year: 2016
    ..Thrombolytic therapy with tissue plasminogen activator (tPA) is the only approved treatment for ischemic stroke, but its use carries a significant risk for increased incidence ..
  5. ERIK IAN TUCKER; Fiscal Year: 2016
    ..Existing antithrombotic and thrombolytic drugs, such as recombinant tissue plasminogen activator (TPA) cause bleeding and, thus, cannot be used at their fully effective doses...
  6. Keith B Neeves; Fiscal Year: 2014
    ..Tissue plasminogen activator (tPA), a common clot buster, has been used to treat thrombotic clots but can lead to excessive bleeding and must be used ..
  7. Phillip Zhe Sun; Fiscal Year: 2016
    ..Whereas FDA-approved tissue plasminogen activator (tPA) is a potent thrombolytic agent for treating acute ischemic stroke, few patients present for treatment within its ..
  8. Imaging Study of Combination Thrombolytic Therapy
    GEORGE JEROME SHAW; Fiscal Year: 2010
    ..Currently, the only FDA approved therapy is the administration of tissue plasminogen activator (tPA) within 3 hours of stroke onset...
  9. Development of Stroke Point of Care Immunoassay for Cellular Fibronectin
    Albert K Man; Fiscal Year: 2010
    ..which comprises approximately four-fifths of all strokes, thrombolytic therapy by tissue plasminogen activator (tPA) has been proven to be effective in the critical first 3 hours from symptom onset...
  10. Thrombolysis in Pediatric Stroke Study (TIPS)
    Catherine M Amlie-Lefond; Fiscal Year: 2013
    ..I study which will establish the safety, dosing and pharmacokinetics of intravenous (tissue plasminogen activator) tPA for childhood stroke...
  11. Transcranial Laser Therapy of Ischemic Stroke
    Piyush M Patel; Fiscal Year: 2013
    ..e. intracerebral hemorrhage [ICH]). Even thrombolytic therapy with tissue plasminogen activator (tPA) produces complete resolution of symptoms less than 40% of the time, so there is need for additional forms of ..
  12. Identification of PKC delta Substrates in Stroke-reperfusion Injury
    Wen Hai Chou; Fiscal Year: 2009
    ..This proposal is to identify the targets of protein kinase C delta, and the information obtained will facilitate the development of new therapies to limit stroke- reperfusion injury. ..
  13. Zhongwu Liu; Fiscal Year: 2014
    ..stroke is enhanced by MSC treatment via astrocytic increase in the net activity of tissue plasminogen activator (tPA) via modifying the balance of tPA/plasminogen activator inhibitor-1(PAI-1) level...
  14. Workshop on the Molecular and Cellular Biology of Plasminogen Activation
    Victoria Ploplis; Fiscal Year: 2013
    ..primary physiological activators, urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA), resulting in formation of stable serpin/protease complexes...
  15. ULTRASOUND ENHANCED THROMBOLYSIS FOR ISCHEMIC STROKE
    Andrei Alexandrov; Fiscal Year: 2004
    ..shown that various ultrasound frequencies can enhance clot lysis in the presence of tissue plasminogen activator (TPA)...
  16. Jinyuan Zhou; Fiscal Year: 2015
    ..Currently, the only FDA- approved treatment for ischemic stroke is intravenous tissue plasminogen activator (IV tPA) that is given within three hours of symptom onset...
  17. A Novel Intervention Strategy for Stroke with RTL Therapy
    Halina Offner; Fiscal Year: 2013
    ..Finally, 3) that RTL1000 is an effective therapy when combined with tissue plasminogen activator (tPA)...
  18. Emilio B Gonzalez; Fiscal Year: 2014
    ..There is strong evidence that annexin A2, a receptor for tissue plasminogen activator (tPA) and plasminogen, and toll-like receptor 4 (TLR-4), a receptor for bacterial lipopolysaccharide (LPS) and ..
  19. Treatment of stroke with a clinically approved proteasome inhibitor
    Li Zhang; Fiscal Year: 2012
    ..Thrombolysis with tissue plasminogen activator (tPA) promotes adverse vascular events that limit the therapeutic window of stroke to three hours...
  20. Plasminogen activators and NMDA after brain injury
    William M Armstead; Fiscal Year: 2012
    ..Urokinase and tissue plasminogen activator (uPA and tPA) are serine proteases whose contributions to the regulation of cerebral hemodynamics are not well characterized...
  21. Zheng Gang Zhang; Fiscal Year: 2016
    ..Tissue plasminogen activator (tPA) is the only drug approved by the Food and Drug Administration (FDA) for treatment of acute stroke (within 4.5h)...
  22. Transcranial Sonothrombolysis with Diagnostic Ultrasound
    Thilo Hoelscher; Fiscal Year: 2013
    ..UCA) potentiate the effect of sonothrombolysis, without or in combination with tissue Plasminogen Activator (tPA)...
  23. Christian Rask-Madsen; Fiscal Year: 2016
    ..mortality, occurrence of symptomatic ICH in stroke patients treated with intravenous tissue plasminogen activator (tPA), and increased hematoma volume and expansion, which are significant and independent determinants of poor clinical ..
  24. Weibel-Palade Bodies: roles in thrombosis, inflammation and stroke
    Denisa D Wagner; Fiscal Year: 2013
    ..in stroke, b) Therapeutic effect of rADAMTS13 in ischemic stroke and comparison to tissue plasminogen activator (tPA). The application heavily relies on genetically modified mice, all available to our laboratory...
  25. Novel Methods for Dissolving Blood Clots
    GUY LELAND REED; Fiscal Year: 2013
    ..Tissue plasminogen activator (TPA) and other blood clot-dissolving drugs are better at preventing post-thrombotic symptoms, but the high doses used ..
  26. Pulmonary Formulation of tPA for Plastic Bronchitis
    Kathleen A Stringer; Fiscal Year: 2010
    ..Presently, PB is anecdotally treated with inhaled tissue plasminogen activator (tPA) with no evidence for safety or efficacy...
  27. VINOD D LABHASETWAR; Fiscal Year: 2014
    ..Further, nano-SOD/catalase could prevent neuroinflammation and facilitate neuronal repair mechanisms that could significantly improve the post-stroke recovery. ..
  28. Li Zhang; Fiscal Year: 2016
    ..Currently, tissue plasminogen activator (tPA) is the only thrombolytic drug approved by FDA for the treatment of ischemic stroke...
  29. GREGORY JAYE BIX; Fiscal Year: 2014
    ....
  30. Jieli Chen; Fiscal Year: 2014
    ..However, tPA does not reduce lesion volume nor improve functional outcome, but increases the incidence of brain hemorrhage and ..
  31. Acute Stroke Program of Interventions: Racial &Ethnic Disparities(ASPIRE)
    CHELSEA M KIDWELL; Fiscal Year: 2011
    ..have suggested that blacks are less likely than whites to receive intravenous tissue plasminogen activator (IV tPA), the only FDA-approved acute ischemic stroke therapy...
  32. Annexin 2 in Lymphoproliferative Angiogenesis
    Jia Ruan; Fiscal Year: 2012
    ..Annexin 2 (A2) is a fibrinolytic protease receptor that binds plasminogen and tissue plasminogen activator (tPA) at the surface of endothelial cells and monocyte/macrophages...
  33. Factor XI Inhibition for the Treatment of Ischemic Stroke
    ERIK IAN TUCKER; Fiscal Year: 2012
    ..Early use of tissue-type plasminogen activator (tPA, Activase(R)), currently the only FDA-approved treatment for AIS, can promote reperfusion via thrombolysis...
  34. A Novel Ultrasound Phased Array and Sonication Method for Stroke Treatments
    Kullervo Hynynen; Fiscal Year: 2012
    ..that will have recanalization of the occluded vessel when administrated together with tissue plasminogen activator (tPA)...
  35. Piyush Patel; Fiscal Year: 2014
    ..applicant): Acute ischemic stroke is now a treatable condition with the thrombolytic, tissue plasminogen activator (tPA)...
  36. Who Benefits from tPA 3-6 hours after Stroke
    Maarten G Lansberg; Fiscal Year: 2010
    Currently, the only FDA approved treatment for acute stroke is intravenous tissue plasminogen activator (iv tPA) administered within three hours after symptom onset...
  37. Michael Chopp; Fiscal Year: 2015
    ..We propose that when administered after stroke, MSCs activate tissue plasminogen activator (tPA) within parenchymal cells, and tPA mediates neurite remodeling leading to improvement in neurological function...
  38. Hypothermia in Acute Stroke with Thrombolysis Imaging Evaluation of Revasculariza
    DAVID SIGMUND LIEBESKIND; Fiscal Year: 2013
    ..and reperfusion with standard thrombolytic treatment with intravenous (IV) tissue plasminogen activator (tPA) for acute ischemic stroke in humans...
  39. Phenylpropanoid Analogs to Treat Stroke
    Paul A Lapchak; Fiscal Year: 2012
    ..resulting from an embolism is now a treatable condition, because thrombolysis with tissue plasminogen activator (tPA) has been approved by the FDA...
  40. Protein S: Neurovascular Protection in Stroke
    Berislav V Zlokovic; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Tissue plasminogen activator (tPA) thrombolysis is beneficial for thrombotic stroke, but its direct neuronal and vascular toxicities are problematic...
  41. GUY LELAND REED; Fiscal Year: 2014
    ..Tissue plasminogen activator (TPA), an agent that catalyzes the dissolution of blood clots, is the only effective, FDA-approved treatment for ..
  42. BIOMEDICAL (BASIC)
    Nancy R Cook; Fiscal Year: 2009
    ..and Reynolds models, including lipoprotein-associated phospholipase A2 (Lp-PLA), tissue plasminogen activator (tPA antigen), and amino-terminal pro-B-type natriuretic peptide (proBNP), In addition, we will refine methods for the ..
  43. Proteases in IOP-mediated glaucomatous damage
    Shravan K Chintala; Fiscal Year: 2010
    ..This application will test the hypothesis that proteases, tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA), up-regulated by elevated IOP cause RGC loss and inhibition of these ..
  44. LESLI ELIZABETH SKOLARUS; Fiscal Year: 2016
    ..Despite the fact that tissue plasminogen activase (tPA), decreases post-stroke morbidity, mortality and is cost saving, it is underutilized especially among African ..
  45. ENDOTHELIAL CELL DIVERSITY DURING FETAL DEVELOPMENT
    Eugene Levin; Fiscal Year: 2001
    ..Using tissue plasminogen activator (tPA) expression as an endothelial cell marker, we have found a pattern of progressive and transitory tPA expression in ..
  46. MECHANISMS OF HEMORRHAGE AND EDEMA IN TPA STROKE THERAPY
    ENG LO; Fiscal Year: 2006
    A major problem with tissue plasminogen activator (tPA) therapy for ischemic stroke is the complication of hemorrhage and edema...
  47. Ischemic Brain Damage & Triple/Single Quantum Sodium MRI
    Fernando Boada; Fiscal Year: 2006
    ..The introduction of reperfusion therapy using tissue plasminogen activator (tPA) revolutionized the treatment of stroke by providing an aggressive means to reverse the ischemic insult...
  48. Mechanical Clot Obliteration for the Treatment of Stroke
    Matthew Gounis; Fiscal Year: 2009
    ..currently only two FDA-approved therapies: (1) Pharmacologic clot dissolution with tissue plasminogen activator (tPA);and (2) Mechanical thrombectomy with a basket-type mechanical device, the Merci retriever...
  49. TPA MEDIATED NEURODEGENERATION AND MICROGLIA ACTIVATION
    STYLIANI ANNA STELLA TSIRKA; Fiscal Year: 2001
    ..We have found that tissue plasminogen activator (tPA), a serine protease that converts plasminogen to plasmin, mediates neuronal cell death in the hippocampus...
  50. TISSUE PLASMINOGEN ACTIVATOR AND NEURONAL DEGENERATION
    Sidney Strickland; Fiscal Year: 2004
    The protease tissue plasminogen activator (tPA) has been implicated in neuronal death in the central nervous system (CNS). We have now found that tPA also affects neurons after damage in the peripheral nervous system (PNS)...
  51. PROTEASES IN NERVOUS SYSTEM FUNCTION AND DYSFUNCTION
    RANDALL PITTMAN; Fiscal Year: 2000
    DESCRIPTION Tissue plasminogen activator (tPA), a serine protease with limited proteolytic activity, is present in high concentrations in the adult nervous system...
  52. PAI-1 Targeted Intrapleural Fibronolytic Therapy
    Andrey Komissarov; Fiscal Year: 2012
    ..implicated in the pathogenesis of pleural loculation and inhibits tissue and urokinase plasminogen activators;tPA and uPA, which are currently used for IPFT...
  53. Carl W White; Fiscal Year: 2015
    ..chlorine concentrations, b) coagulation activation in the CEES inhalation and chlorine models, and c) efficacy of tPA (tissue-type plasminogen activator) in late rescue, starting 4h after CEES inhalation...
  54. Delivery of Anti-thrombotic Drugs by Blood Cells
    Vladimir R Muzykantov; Fiscal Year: 2012
    ..demonstrated a proof of principle for effective and safe thromboprophylaxis attained by re-infusion of RBC/tPA conjugates in animals (Nature Biotech 2003);and, iii) designed safe loading of circulating RBC by anti-RBC/tPA ..
  55. Yves A DeClerck; Fiscal Year: 2016
    ..that controls the activation of plasminogen into plasmin by tissue and urokinase type plasminogen activators (tPA and uPA, respectively). In the past, PAI-1 was considered to be anti-tumorigenic...
  56. Vladimir R Muzykantov; Fiscal Year: 2016
    ..protein receptor (LRP1) and N-methyl-D-aspartate (NMDA) receptors (NMDARs) in the pulmonary vasculature by uPA (and tPA) which disrupts pulmonary arterial EC barrier function and deregulates vascular tone, offsetting the salutary ..
  57. ABD ALROOF HIGAZI; Fiscal Year: 2014
    ..We postulate that marked release of the fibrinolysis initiators, tissue type plasminogen activator (tPA) and urokinase plasminogen activator, from the injured brain leads to both: 1) premature clot ..
  58. VON WILLEBRAND FACTOR, FIBRINOLYSIS, & THE ENDOTHELIUM
    Karen Hamilton; Fiscal Year: 1991
    ..These cells synthesize von Willerbrand factor (vWF), tissue-type plasminogen activator (tPA), and plasminogen-activator inhibitor (PAI), and vWF and tPA often seem to be released together in vivo in response ..
  59. White Matter Protection in Acute Ischemic Stroke
    Chia Yi Kuan; Fiscal Year: 2012
    ..In Aim 1, we will test the hypothesis that the combination of tPA and Edaravone, an anti-oxidant, is needed for the maximal protection of WM in stroke...
  60. Specialized Programs of Translational Research in Acute Stroke at the Partners
    Steven M Greenberg; Fiscal Year: 2013
    ..5 hours duration, then these patients could be considered for alteplase treatment under current American Heart Association (AHA) guidelines, and be treated if eligible according to the ..
  61. REGULATION OF PROUROKINASE-MEDIATED FIBRINOLYSIS BY ZINC
    S Husain; Fiscal Year: 1990
    Urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) are believed to play a role in thrombolysis as well as localized degradation of extracellular matrix proteins...
  62. Xiaoying Wang; Fiscal Year: 2014
    DESCRIPTION (provided by applicant): Intravenous administration of recombinant tPA remains the most beneficial proven intervention for emergency treatment of stroke...
  63. tPA Neurotoxicity in Hypoxic-Ischemia Encephalopathy
    Chia Yi Kuan; Fiscal Year: 2009
    ..that ischemia-hypoxia produces a rapid induction of tissue-type and urokinase-type plasminogen activators (tPA and uPA) that coincides with transient thrombosis...
  64. Normobaric Hyperoxia in Acute Ischemic Stroke
    Aneesh B Singhal; Fiscal Year: 2010
    ..We believe that today, with enhanced reperfusion rates from newer therapies such as tPA, and advances in MRI that allow serial assessment of tissue ischemia-reperfusion, there exists an exciting ..
  65. Safety of Lung Delivered Tissue Plasminogen Activator
    KATHLEEN STRINGER; Fiscal Year: 2006
    ..I STTR funding supported the successful determination of a feasible formulation of tissue plasminogen activator (tPA) for pulmonary delivery...
  66. Diffusion weighted imaging Evaluation For Understanding Stroke Evolution2:DEFUSE
    Gregory W Albers; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Intravenous (IV) administration of tissue plasminogen activator (tPA) is an effective therapy for acute stroke when treatment is begun within 3 hours of symptom onset...

Patents3

  1. Novel fibrinolytic enzymes
    Patent Number: EP0297066-A1; Date:1988-12-28
  2. Preparation of human tissue plasminogen activator (t-PA) by the microbiological way and conversion of the so obtained enzyme in its active form
    Patent Number: EP0236209-A1; Date:1987-09-09
  3. New tissue plasminogen activator
    Patent Number: EP0379890-A1; Date:1990-08-01